Funk Cleo S M, Hart Xenia M, Gründer Gerhard, Hiemke Christoph, Elsner Björn, Kreutz Reinhold, Riemer Thomas G
Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany.
Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Front Psychiatry. 2022 Feb 21;13:826138. doi: 10.3389/fpsyt.2022.826138. eCollection 2022.
Inter-individual differences in antidepressant drug concentrations attained in blood may limit the efficacy of pharmacological treatment of depressive disorders. Therapeutic drug monitoring (TDM) enables to determine drug concentrations in blood and adjust antidepressant dosage accordingly. However, research on the underlying assumption of TDM, association between concentration and clinical effect, has yielded ambiguous results for antidepressants. It has been proposed that this ambiguity may be caused by methodological shortcomings in studies investigating the concentration-effect relationship. Guidelines recommend the use of TDM in antidepressant treatment as expert opinion. This reflects the lack of research, particularly systematic reviews and meta-analyses of randomized controlled trials, on the relationship between concentration and effect as well as on the benefits of the use of TDM in clinical practice. In this study, a systematic review and meta-analysis of randomized controlled trials has been performed to investigate the relationship between antidepressant concentration, efficacy, and side effects. It is the first meta-analytical approach to this subject and additionally considers methodological properties of primary studies as moderators of effect in quantitative analysis. Our results identified methodological shortcomings, namely the use of a flexible dose design and the exclusion of concentrations in lower- or subtherapeutic ranges, which significantly moderate the relationship between antidepressant concentration and efficacy. Such shortcomings obscure the evidence base of using TDM in clinical practice to guide antidepressant drug therapy. Further research should consider these findings to determine the relationship between concentration and efficacy and safety of antidepressant treatments, especially for newer antidepressants.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=246149, identifier: CRD42021246149.
血液中抗抑郁药物浓度的个体差异可能会限制抑郁症药物治疗的疗效。治疗药物监测(TDM)能够测定血液中的药物浓度,并据此调整抗抑郁药物剂量。然而,关于TDM的潜在假设,即浓度与临床效果之间的关联,抗抑郁药物的研究结果并不明确。有人提出,这种不明确性可能是由于研究浓度-效应关系的方法存在缺陷。指南建议将TDM用于抗抑郁治疗,但这只是专家意见。这反映出缺乏关于浓度与效应之间的关系以及TDM在临床实践中使用的益处的研究,尤其是对随机对照试验的系统评价和荟萃分析。在本研究中,我们对随机对照试验进行了系统评价和荟萃分析,以研究抗抑郁药物浓度、疗效和副作用之间的关系。这是针对该主题的首个荟萃分析方法,并且在定量分析中还将原始研究的方法学特性作为效应的调节因素。我们的结果发现了方法学上的缺陷,即使用灵活剂量设计以及排除较低或亚治疗范围的浓度,这些缺陷显著调节了抗抑郁药物浓度与疗效之间的关系。此类缺陷模糊了在临床实践中使用TDM指导抗抑郁药物治疗的证据基础。进一步的研究应考虑这些发现,以确定抗抑郁治疗的浓度与疗效及安全性之间的关系,特别是对于新型抗抑郁药物。
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=246149,标识符:CRD42021246149。